Open AccessSuccessful treatment after toxic epidermal necrolysis induced by AZD-9291 in a patient with non-small cell lung cancer: A case report
Author(s) -
Wen Li,
Xiang He,
Hui Liu,
Jinge Zhu,
Huimin Zhang
Publication year - 2021
Publication title -
world journal of clinical cases
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.368
H-Index - 10
ISSN - 2307-8960
DOI - 10.12998/wjcc.v9.i29.8846
Subject(s) - medicine , toxic epidermal necrolysis , erlotinib , t790m , lung cancer , epidermal growth factor receptor , osimertinib , dermatology , erythroderma , gefitinib , oncology , cancer
Toxic epidermal necrolysis and Stevens-Johnson syndrome are acute life-threatening skin reactions. AZD9291 has been developed as a third-generation epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI) with activity against T790M mutation.